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Introduction
B-cell chronic lymphocytic leukaemia (B-CLL) is
characterized by accumulation of monoclonal long-
living CD5+/CD19+, CD23+, CD21+, CD40+ B lym-
phocytes in bone marrow, peripheral blood and lym-
phoid organs. Irrespective of its phenotypic homogen-
ity, B-CLL is clinical heterogeneous. The mutation sta-
tus of immunoglobulin heavy chain (IgVH) genes,
expression of ZAP70, and CD38, are used as markers
of the clinical heterogenity [1,2]. Numerous experi-
mental data indicate that B-CLL development and pro-
gression are influenced by antigenic pressure. It can't
be excluded that these antigens may originate from
bacteria and viruses.The humoral immune system
senses microbes via recognition of specific microbial
molecular motifs by Toll-like receptors (TLRs) [3].
There are evidences that endogenous TLRs ligands or
chronic infections promote tumor growth [4]. TLRs
are currently used to target different subclasses of B-
cell leukemia, and TLR agonists are being evaluated in
clinical trials. It is little known regarding the repertoire
and function of TLR in B-CLL. The family of TLR
includes 11 different transmembrane proteins answer-
able for recognition of specific pathogen-associated
molecular patterns [5].
Lipopolysaccharide (LPS) is a major gram-nega-
tive bacterial component that stimulates innate
response and also induces B-lymphocyte activation
[3,5]. LPS activates B cells through two known recep-
tors: TLR4 (CD284) and CD180 (previously called
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RP105). TLR4 is essential for signaling via LPS and
requires another molecule, MD-2 which is associated
with extracellular domain of TLR4 [6]. CD180 struc-
turally resembles TLRs (except Toll/IL -1 receptor
(TIR) domain) and it promotes LPS-driven B-cell
responses. CD180 creates a complex with MD1 which
is structurally related to TLR4/MD-2 complex [7]
CD180 is B-cell specific while TLR4 is universally
expressed, and each of them uses distinct pathways.
LPS binding to CD180/MD1 induces Lyn activation
and CD19 phosphorylation whereas LPS binding to
TLR4/MD-2 activates MyD88/IRAK and MyD88-inde-
pendent TIRAP pathways to activate JNK and NFκB
[8,9,10]. CD14 functions as a co-receptor for LPS [11].
The role of CD14 in TLR4 signaling consists of binding
LPS and presenting it to MD-2 and TLR4 [12,13].
The aim of the present study was to assess the
CD180, CD284 and mCD14 levels in CD19+ subpopu-
lation of B-CLL peripheral blood lymphocytes and com-
pare them with respective levels in the normal B-cells of
adult volunteers, before and after LPS stimulation. 
Materials and methods 
Patients. Fifteen patients with newly diagnosed or untreated
chronic lymphocytic leukemia (B-CLL) were included in this
analysis (median age 64, range: 45-79 years). Patients were diag-
nosed at the Department of Haematooncology and Bone Marrow
Transplantation of the Medical University in Lublin. The diagnosis
was made according to standard criteria: clinical, morphological
and immunophenotypic features of B-CLL. The total lymphocyte
count ranged from 10.54 to 638 × 109/L. Stage of the disease was
determined according to Rai classification (14). Patients were
graded as follows: stage 0 (2 cases), stage I (3 case), stage II (5
cases) stage III (3 cases), and stage IV (2 cases). A group ten of
healthy blood donors (median age 55, range: 46-67) was used as
control group.
Peripheral blood mononuclear cells (PBMCs) were obtained
from patients with B-CLL, and from healthy controls by density
gradient centrifugation over Lymphoprep (Nycomed, Pharma AS,
Norway).
Flow cytometry analysis. For two-color and triple direct staining
flow cytometry, (FACSCalibur, Becton Dickinson Immunocytom-
etry System) PBMCs (1×106 cells) suspended in staining buffer
(phosphate buffered saline supplemented with 1.0% fetal calf
serum and 0.1% sodium azide, pH 7.4) were incubated with com-
mercial mouse monoclonal antibodies [anti-human CD19/Cy-
Chrome (PE-Cy5), anti-human CD5/FITC, anti-human CD14/FITC,
anti-human CD180/PE anti-human CD284/FITC] and respective
immunoglobulin isotype controls. Staining was performed accord-
ing to supplier instructions for 20 min on ice. 
The percentage of cells was calculated on the basis of data
obtained from two-color immunofluorescence dot-blots. Analyses
were carried out using CellQUEST Software (Becton Dickinson)
on gated lymphocytes. Quadrant markers were set relative to neg-
ative immunoglobulin isotype controls in such a way that 98-99%
of the cells labeled with the control antibodies were located in
lower left (LL) quadrant. 
CD180, CD284, and mCD14 expression was evaluated as
mean fluorescence intensity (MFI) on gated CD19+CD180+,
CD19+/CD284+ and CD19+/CD14+ lymphocyte population. MFI
was calculated as a ratio of mean value of the fluorescence of the
test over that of the control. 
Lymphocyte cultures. Human peripheral blood (PB) lymphocytes
and B-CLL cells were cultured in RPMI-1640 medium (Gibco)
containing FCS (fetal calf serum) (10%), HEPES (10 mM), gluta-
mine 2 mM, streptomycin (100μg/ml), penicillin (100 IU/ml)
(Polfa, Poland), on culture plates (106 cells/ml) (Corning Inc,
USA) at 37°C in humidified 5% CO2 atmosphere for 24 hours.
Lymphocytes were stimulated by LPS (50 μg/ml) (Sigma). 
Statistical analysis. All results are shown as mean value, with
standard deviation. Statistical significance of the differences




Immunophenotyping was performed by dual- and
triple- color flow-cytometry analysis of peripheral
blood samples CD19+. The mean percentage of CD19+
lymphocytes in normal controls was 7.2% (SD: 2.57)
and in CLL patients was 91% (SD: 5.01).
As demonstrated by CD19+/CD5+ co-expression
analysis, the vast majority of B cells analyzed were
malignant CLL cells (mean 80.44%) (Fig.1).
CD19+/CD5+ co-expression was found only in 2.75%
of normal PBL, the difference was statistically signifi-
cant (p=0.0027).
We determine the percentage and MFI of the
CD180, CD284, and CD14 positive cells among
CD19+ B-CLL normal B cells. The percentage of sub-
population CD19+CD180+ did not differ significantly
between analyzed groups of patients and healthy
donors (87.4% in B-CLL and 90.9% in normal cells).
CD284 expression was found only in 1.8% of CD19+
normal B cells and 1.1% of CD19+ B CLL cells. Sim-
ilarly, the percentage of CD19+/CD14+ population was
very low. In normal control was 1.5% and only 0.2%
in B-CLL (Fig. 2)
Using flow cytometry MFI was analyzed. The
analysis included of CD180, CD284 and CD14 MFI
on the CD19+ cell surface. We have shown that CD180
expression of unstimulated normal B cells was four
time higher in comparison with unstimulated CLL B
cells (MFI: 99.16 vs 25.3; p=0.0007). Moreover, the
expression CD284 in normal B cells was insignificant-
ly higher than in CLL (MFI: 7.37 vs. 5.79; p=0.37).
However CD14 MFI was significantly higher in nor-
mal B cells (25.07 vs. 8.32; p=0.001). Table 1 contains
detailed results. 
After 24 hour LPS activation of B-cells, the signif-
icant differences of CD180 expression were observed.
CD180 expression decreased after 24 hour LPS stimu-
lation in normal and leukemic CD19+ cells. CD284
after LPS stimulation insignificantly decreased in
healthy controls (mean 6.16 vs. 7.37 before LPS stim-
ulation). In contrast, we observed very slight increase
of MFI (mean 6.26 after vs. 5.79 before LPS stimula-
tion) in leukemic cells. CD14 MFI in leukemic cells
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Fig. 1. Expression examples of
CD19+/CD5+ (A) and CD19+/CD180+
(B) in CLL B cells, CD19+/CD180+
(C) in normal B cells (I – an isotype
control, II – B cells of CLL population).
Fig. 2. The mean percentage of  1)
CD19+/CD180+, 2) CD19+/CD284+, 3)
CD19+/CD14+ cells among CD19+ nor-
mal (A) and CLL (B) B cells.
was somewhat higher after LPS in comparison to
CD14 MFI without LPS stimulation (10.63 vs. 8.32),
whereas CD14 MFI in normal CD19+ cells after LPS
stimulation decreased over three times (25.07 vs.
7.48).
Discussion 
The recent view claims that CLL is accumulative dis-
ease associated with higher level of leukocytes prolif-
eration [15]. New evidences suggest that antigenic
stimulation, along with lymphocyte interaction with
accessory cells and cytokines, are promoting factors
that stimulate proliferation of CLL cells and allow
them to avoid apoptosis. The existing hypothesis sug-
gests that antigen stimulation is generally a prerequi-
site for the evolution of B-CLL [15]. These promoting
antigens are unknown. However, it is possible that
latent viruses or commensal bacteria repetitively acti-
vate particular B-cell clones through the B-cell recep-
tor (BCR). Mature B-cells can recognize microbial
antigens also via Toll-like receptors in costimulatory
manner at least in the context of autoimmune reac-
tions. However, it is little known regarding the reper-
toire and function of TLR in CLL cells. The TLR fam-
ily includes 11 different transmembrane proteins
which are engaged in recognition of specific pathogen-
associated molecular patterns [6]. TLR receptors also
take part in alarming immunocompetent cells to trig-
ger an immune response. 
The endogenous TLR ligands or chronic infections
are suggested to promote tumor growth [4]. Muzio et
al. [16] found that CLL cells express several TLR pat-
tern-recognition molecules and that the specific TLR
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Table 1. Mean percentage of CD19+, CD19+CD180+, CD19+CD14+ and CD19+CD284+ of normal and leukemic lymphocytes, without
and after 24 hour LPS stimulation. MFI of CD180, CD284 and CD14 on the CD19+ surface lymphocytes.
Fig. 3. Mean MFI of CD180, CD284 and CD14 on the CD19+ surface lymphocytes
Fig. 4. MFI of cell surface CD180 (A), CD284 (B), CD14 (C) molecules expression in unstimulated and 24 hours LPS stimulated B-CLL
and control (normal) B cells. 
expressed by CLL cells are functional [4,17]. The sus-
ceptibility to infections induced by Gram-negative
bacteria is largely determined by innate immune
responses to bacteria cell wall lipopolysaccharide
(LPS). The stimulation of B cells by LPS enhances
their antigen-presenting capacity and is accompanied
by B cell proliferation and secretion of large quantities
of LPS-neutralizing antibodies. Ogata et al. [8]
demonstrated the functional cooperation between
CD284 and CD180 in LPS-mediated nuclear factor κB
activation. The CD180 protein plays significant role in
B cell development acting both as LPS sensor and reg-
ulator of B cell proliferation [8]. The LPS effect on
regulation of TLR may be due to either direct impact
or to autocrine stimulation by secreted factors such as
cytokines. A variety of cytokines induced by LPS may
also alter TLR expression. 
We assessed levels of the CD284, CD180 and co-
receptor for LPS – mCD14 in CD19+ subpopulation of
B-CLL lymphocytes and compared them with respec-
tive levels obtained from the normal B cells, before
and after LPS stimulation. Mentioned molecules
employ signals from LPS [18].
CD284 expression in normal as well as leukemic
CD19+ cells was poor. The mean fluorescence intensi-
ty (MFI) in normal lymphocytes decreased after LPS
stimulation while slight increase of MFI was observed
in leukemic cells. Increased mRNA levels CD284 in
the monocytic leukemia line THP-1 after LPS treat-
ment was also observed by Zarember and Godowski
[19]. CD14 MFI in leukemic cells was moderately
higher after LPS in comparison to CD14 MFI without
LPS stimulation, whereas CD14 MFI in normal CD19+
cells after LPS stimulation decreased over three times.
However, the significant differences of CD180 expres-
sion were observed. CD180 expression was decreased
after 24 hour LPS stimulation in normal and leukemic
CD19+ cells.
Our study confirm the results of Zarember and
Godowski [19], who observed 100-fold down regula-
tion of CD180 expression in monocytic leukaemia cell
line THP-1 after LPS stimulation. The observed in the
present study decrease of CD180 protein on lympho-
cytes surface after LPS stimulation, correlating with
mentioned decrease of mRNA expression [19] seems
to be natural reaction on ligand-receptor binding.
Four-time lower CD180 expression in unstimulated
peripheral blood CD19+ CLL cells, in comparison with
normal lymphocytes CD19+, may indicate constant
stimulation of CD180 receptor in CLL by unknown
antigen or auto-antigen. It can not be excluded that
chemical structure of unknown antigen resembles
lipopolysaccharide of Gram- negative bacteria. 
Recently CD180 was found to have regulatory
function and inhibits TLR4-signalling [20].
CD180/MD-1 interacts directly with TLR-4/MD-2,
inhibiting the ability of this signaling complex to bind
LPS [17,20,21]. Double increase of CD284 MFI after
LPS stimulation in CLL cells may imply impairment
of CD180 inhibiting function in leukaemia.
TLR transduction signaling pathway in CLL has
been the subject of intensive study for the last several
years. The hypothesis of low-affinity antigen or auto-
antigen existence, exerting constant impact on B-CLL
cells, has become more and more popular [15,22].
Muzio et al. [23] provides molecular evidence, that
constitutive activation of B cells may be responsible
for anergic state of human B lymphocytes. At the same
time Chiron et al. [4] suggested that repeated poly-
clonal activation of leukemic B cells by microbial mol-
ecules during natural infections or inflammation may
initiate the oncogenic process .
The discovery and defining potential antigens and
their function in interacting with both BCR or/and
TLR receptors might be useful in specific B-CLL ther-
apy. Many existing information in literature about pos-
sible role of antigenic stimulation in CLL seem to con-
firm this idea.
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